Ameriprise Financial Inc. Has $6.81 Million Stock Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Ameriprise Financial Inc. cut its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 9.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 84,557 shares of the company's stock after selling 8,532 shares during the quarter. Ameriprise Financial Inc. owned about 0.16% of PROCEPT BioRobotics worth $6,809,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC raised its holdings in shares of PROCEPT BioRobotics by 295.8% in the 4th quarter. SG Americas Securities LLC now owns 6,598 shares of the company's stock worth $531,000 after purchasing an additional 4,931 shares in the last quarter. Chicago Capital LLC increased its stake in shares of PROCEPT BioRobotics by 44.5% during the 4th quarter. Chicago Capital LLC now owns 379,582 shares of the company's stock worth $30,564,000 after purchasing an additional 116,931 shares during the last quarter. Matisse Capital boosted its holdings in shares of PROCEPT BioRobotics by 112.9% during the 4th quarter. Matisse Capital now owns 22,285 shares of the company's stock worth $1,794,000 after buying an additional 11,817 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of PROCEPT BioRobotics by 218.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 401,210 shares of the company's stock worth $33,350,000 after buying an additional 275,071 shares during the period. Finally, KBC Group NV boosted its holdings in shares of PROCEPT BioRobotics by 46.0% during the 4th quarter. KBC Group NV now owns 2,236 shares of the company's stock worth $180,000 after buying an additional 705 shares during the period. 89.46% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

PRCT has been the subject of a number of research reports. Bank of America reduced their price target on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating for the company in a report on Friday, April 25th. Wall Street Zen raised shares of PROCEPT BioRobotics from a "sell" rating to a "hold" rating in a report on Saturday. Truist Financial decreased their price objective on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, April 11th. Finally, Morgan Stanley lowered their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $90.00.

PROCEPT BioRobotics Stock Down 0.4%

PRCT traded down $0.24 during trading on Wednesday, reaching $58.30. The company had a trading volume of 70,494 shares, compared to its average volume of 816,060. The business's fifty day moving average price is $55.28 and its 200 day moving average price is $70.08. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. The company has a market cap of $3.23 billion, a P/E ratio of -29.83 and a beta of 1.10. PROCEPT BioRobotics Co. has a 12 month low of $47.04 and a 12 month high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.04. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business had revenue of $69.16 million for the quarter, compared to analyst estimates of $65.39 million. During the same quarter in the previous year, the firm posted ($0.51) earnings per share. The firm's revenue for the quarter was up 55.5% on a year-over-year basis. Equities analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

Insiders Place Their Bets

In other PROCEPT BioRobotics news, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the transaction, the chief financial officer now directly owns 107,991 shares of the company's stock, valued at $6,161,966.46. This trade represents a 0.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Reza Zadno sold 5,475 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the completion of the transaction, the chief executive officer now directly owns 173,070 shares in the company, valued at approximately $9,875,374.20. This represents a 3.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,455 shares of company stock valued at $368,322. 6.60% of the stock is currently owned by corporate insiders.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).